Mok, Beverly Y.
Kotrys, Anna V. http://orcid.org/0000-0003-4983-1414
Raguram, Aditya
Huang, Tony P. http://orcid.org/0000-0003-2904-830X
Mootha, Vamsi K. http://orcid.org/0000-0001-9924-642X
Liu, David R. http://orcid.org/0000-0002-9943-7557
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB027793, R01EB031172)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
Howard Hughes Medical Institute (Liu investigatorship)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01AI142756)
Article History
Received: 19 September 2021
Accepted: 8 February 2022
First Online: 4 April 2022
Competing interests
: The authors declare competing financial interests: B.Y.M., A.R. and D.R.L have filed patent applications on this work. D.R.L. is a consultant for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine, and Resonance Medicine, which are companies that use genome editing, genome engineering, or PACE, and owns equity in these companies. V.K.M. is a consultant to 5am Ventures and Janssen Pharmaceuticals. Direct correspondence to drliu@fas.harvard.edu.